*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Implement targeted therapies for acute myeloid leukemia.
Implement targeted therapies for multiple myeloma.
Assess your ability to review the role and timing of intestinal microbiome in cancer immunotherapy.
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA=Not Applicable
54321NA
Acute Myeloid Leukemia in 2024 - Richard Stone, M.D.
Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D.
YT-200, an Anti-Galectin-9 Antibody in Clinical Development for AML/High-risk MDS - Aleksandra Filipovic M.D. Ph.D.
Immunotherapeutic Approaches to Undruggable Leukemia Targets - David Scheinberg M.D., Ph.D.
CD34+-selected Allografts as Platform for Post-Transplant CAR T-Cell Therapy in AML - Guenther Koehne, M.D., Ph.D.
The Role of Haploidentical Transplants in 2024 - Leo Luznik, M.D.
Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D.
The Role of Auto SCT for Multiple Myeloma in 2024 - Saad Usmani, M.D.
Targeted Therapies for Multiple Myeloma in 2024 - Adam Cohen, M.D.
Optimizing the Management of Relapsed and Refractory Multiple Myeloma in the Era of Immunotherapy - Paul Richardson, M.D.
Galectin-9 as a Therapeutic Primer to Boost Anti-SLAM7 Efficacy in Multiple Myeloma - Charles Dimitroff, Ph.D.
Overview of Cellular and Immunotherapies in South America: Current Status and Unmet Needs - Patricio Duarte, M.D.
*
*
*
*
*
*
*
*